Arvinas (NASDAQ:ARVN) Given Buy Rating at HC Wainwright

Arvinas (NASDAQ:ARVN)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a note issued to investors on Wednesday, Benzinga reports. They presently have a $87.00 price target on the stock. HC Wainwright’s target price would indicate a potential upside of 153.42% from the stock’s current price.

A number of other research analysts also recently commented on the stock. Oppenheimer reaffirmed an “outperform” rating and set a $80.00 price objective (down from $95.00) on shares of Arvinas in a research report on Wednesday, February 28th. Citigroup lowered Arvinas from a “buy” rating to a “neutral” rating and increased their price objective for the stock from $36.00 to $55.00 in a report on Wednesday, February 14th. Leerink Partnrs restated an “outperform” rating on shares of Arvinas in a research note on Thursday, February 22nd. Barclays lifted their price target on Arvinas from $26.00 to $60.00 and gave the company an “overweight” rating in a report on Thursday, February 29th. Finally, Wedbush increased their price objective on Arvinas from $33.00 to $59.00 and gave the stock an “outperform” rating in a report on Wednesday, February 28th. Two investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $59.73.

Arvinas Stock Up 6.4 %

NASDAQ:ARVN opened at $34.33 on Wednesday. Arvinas has a 1-year low of $13.57 and a 1-year high of $53.08. The firm has a market capitalization of $2.35 billion, a price-to-earnings ratio of -5.28 and a beta of 1.95. The stock has a fifty day simple moving average of $39.27 and a 200 day simple moving average of $35.57.

Arvinas (NASDAQ:ARVN) last issued its quarterly earnings results on Tuesday, May 7th. The company reported ($0.97) EPS for the quarter, beating the consensus estimate of ($1.42) by $0.45. Arvinas had a negative net margin of 185.09% and a negative return on equity of 70.24%. The business had revenue of $25.30 million during the quarter, compared to the consensus estimate of $32.94 million. During the same quarter in the prior year, the firm earned ($1.54) EPS. The firm’s quarterly revenue was down 22.2% on a year-over-year basis. Equities analysts predict that Arvinas will post -5.02 earnings per share for the current year.

Insider Buying and Selling

In other news, CFO Sean A. Cassidy sold 1,702 shares of the company’s stock in a transaction dated Friday, February 23rd. The shares were sold at an average price of $47.05, for a total transaction of $80,079.10. Following the completion of the transaction, the chief financial officer now owns 181,916 shares of the company’s stock, valued at $8,559,147.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, insider Ronald Peck sold 1,699 shares of the company’s stock in a transaction dated Friday, February 23rd. The shares were sold at an average price of $47.05, for a total value of $79,937.95. Following the sale, the insider now owns 67,516 shares of the company’s stock, valued at $3,176,627.80. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Sean A. Cassidy sold 1,702 shares of Arvinas stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $47.05, for a total value of $80,079.10. Following the sale, the chief financial officer now directly owns 181,916 shares in the company, valued at $8,559,147.80. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 8,597 shares of company stock valued at $404,489. 5.23% of the stock is owned by company insiders.

Institutional Trading of Arvinas

A number of large investors have recently bought and sold shares of the stock. Strs Ohio lifted its holdings in Arvinas by 67.6% during the 3rd quarter. Strs Ohio now owns 29,000 shares of the company’s stock valued at $569,000 after purchasing an additional 11,700 shares during the last quarter. TD Asset Management Inc boosted its holdings in shares of Arvinas by 100.0% in the 3rd quarter. TD Asset Management Inc now owns 94,872 shares of the company’s stock worth $1,863,000 after acquiring an additional 47,436 shares in the last quarter. Yelin Lapidot Holdings Management Ltd. acquired a new stake in Arvinas during the 3rd quarter valued at $972,000. China Universal Asset Management Co. Ltd. raised its position in Arvinas by 96.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,374 shares of the company’s stock valued at $27,000 after purchasing an additional 674 shares during the last quarter. Finally, M&T Bank Corp boosted its stake in Arvinas by 20.1% in the third quarter. M&T Bank Corp now owns 27,083 shares of the company’s stock worth $532,000 after purchasing an additional 4,528 shares in the last quarter. 95.19% of the stock is currently owned by institutional investors.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.